This novel grading system incorporated new genetic markers—for example, IDH1/IDH2, O6 -mtehylguanine DNA methyltransferase (MGMT), and epidermal growth factor receptors (EGFR)—thereby allowing clinicians to differentiate tumors not only by their cell type and aggressiveness, as was possible with pre-existing methods, but also by the genetic phenotype of the neoplastic cells, thus providing better correlation with the tumor prognosis [2]. Here, EGFR is linked to neoplasm.